Mineralys Therapeutics, Inc. - Common Stock — Filings & Documents (NASDAQ:MLYS) — Page 7 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2022

Annual report, Q4 FY2022

Mineralys Therapeutics, Inc. annual report, Q4 FY2022

1
2
3
4
5
6
7

News

UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target

Mineralys Therapeutics, Inc. (MLYS) Presents at American Heart Association Hypertension Scientific Sessions 2026 - Slideshow (NASDAQ:MLYS) 2026-10-09

Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study

Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,

Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026

Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS)

THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade) (NYSE:THQ)

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular Protection - Slideshow (NASDAQ:MLYS) 2026-06-01

Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript